Neutralizing activity of anti–SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci182919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Lorenza Bellusci und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Immunoglobulins, Intravenous, Antibodies, Neutralizing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FDA Office of Counterterrorism and Emerging Threats (OCET) - Medical Countermeasures initiative.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- FDA Office of Counterterrorism and Emerging Threats (OCET) - Medical Countermeasures initiative
Zitieren
APA
Bellusci, L., Golding, H., & Khurana, S. (2024). Neutralizing activity of anti–SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants. Journal of Clinical Investigation. https://doi.org/10.1172/jci182919
Vancouver
Bellusci L, Golding H, Khurana S. Neutralizing activity of anti–SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants. Journal of Clinical Investigation. 2024. doi:10.1172/jci182919
BibTeX
@article{Bellusci2024,
author = {Bellusci, Lorenza and Golding, Hana and Khurana, Surender},
title = {Neutralizing activity of anti–SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci182919}
}
EUVIMED